NAMS Certified Menopause Practitioner Practice Exam 2026/2027 Comprehensive Exam Mastery Guide: In-Depth Study Companion, Updated Practice Tests, Detailed Test Bank Review, and Advanced Knowledge Assessment ManualQuestion

A 51-year-old woman asks whether her age is typical for natural menopause. Which response is most accurate? A. Natural menopause usually occurs at 35 years B. Natural menopause usually occurs around 51 years C. Natural menopause usually occurs after 65 years D. Natural menopause occurs only after surgical removal of the ovaries Correct Answer: B. Natural menopause usually occurs around 51 years Rationale: The median age of natural menopause is approximately 51 years. Many women experience menopause around this age, although normal variation occurs. Menopause before age 40 is considered premature and requires evaluation. Menopause after age 65 is later than typical. Surgical menopause is different because it results from removal of ovarian function rather than the usual gradual reproductive aging process. Question 2 A 49-year-old woman reports irregular menstrual cycles, hot flashes, and night sweats. She has not gone 12 months without a period. Which reproductive stage best describes her condition? A. Premenopause B. Perimenopause C. Postmenopause D. Primary ovarian insufficiency Correct Answer: B. Perimenopause Rationale: Perimenopause is the transition period before menopause when menstrual cycles become irregular and vasomotor symptoms such as hot flashes and night sweats often appear. The woman has not yet met the definition of postmenopause, which requires 12 consecutive months without menstruation. Premenopause usually refers to regular cycles before the transition. Primary ovarian insufficiency is typically considered when ovarian failure occurs before age 40. Question 3 Which finding most directly reflects the hormonal change responsible for many menopausal symptoms? A. Rising progesterone B. Declining estrogen C. Rising thyroid hormone D. Declining cortisol Correct Answer: B. Declining estrogen Rationale: Declining estrogen is the characteristic hormonal change during the menopausal transition. It contributes to vasomotor symptoms, vaginal dryness, sleep disturbance, bone loss, lipid changes, and genitourinary syndrome of menopause. Progesterone also changes, but estrogen decline is the major driver of many clinical features. Thyroid and cortisol changes may cause symptoms that overlap with menopause, but they are not the defining hormonal change. Question 4 A 53-year-old woman reports that her last menstrual period was 13 months ago. She has had no bleeding since. Which term best describes her reproductive status? A. Early perimenopause B. Late perimenopause C. Postmenopause D. Anovulatory adolescence Correct Answer: C. Postmenopause Rationale: Postmenopause is defined as 12 consecutive months without menstruation, assuming there is no other pathologic or physiologic cause. Since this woman has had 13 months without bleeding, she meets the definition. Early and late perimenopause involve menstrual irregularity before the final menstrual period is confirmed. Anovulatory adolescence is unrelated to the menopausal transition. Question 5 A 52-year-old woman has irregular periods and vasomotor symptoms. Which laboratory result would support the diagnosis of menopause transition? A. Low FSH below 5 IU/L B. Elevated FSH above 25 IU/L C. Elevated hemoglobin A1c D. Low serum sodium Correct Answer: B. Elevated FSH above 25 IU/L Rationale: Elevated follicle-stimulating hormone reflects reduced ovarian feedback as estrogen production declines. In a woman of typical menopausal age with irregular menses and vasomotor symptoms, an FSH level above 25 IU/L can support the diagnosis. However, menopause is often diagnosed clinically. Hemoglobin A1c and sodium may identify other health problems but do not specifically support menopause diagnosis. Question 6 Which treatment is considered most effective for moderate-to-severe menopausal hot flashes in an appropriate candidate? A. Systemic hormone therapy B. Calcium supplementation alone C. Vaginal lubricants alone D. Pelvic floor exercises Correct Answer: A. Systemic hormone therapy Rationale: Systemic hormone therapy is the most effective treatment for moderate-tosevere vasomotor symptoms such as hot flashes and night sweats. It is appropriate only after assessing contraindications and individual risks. Calcium supports bone health but does not control hot flashes. Vaginal lubricants help dryness and dyspareunia. Pelvic floor exercises improve incontinence but do not directly treat vasomotor symptoms. Question 7 A postmenopausal woman with an intact uterus is started on systemic hormone therapy. Which regimen is most appropriate? A. Estrogen alone B. Estrogen plus progestogen C. Testosterone alone D. Bisphosphonate plus calcium only Correct Answer: B. Estrogen plus progestogen Rationale: Women with an intact uterus require progestogen with systemic estrogen to protect the endometrium from estrogen-induced hyperplasia and possible malignancy. Estrogen alone is generally reserved for women who have had a hysterectomy. Testosterone may be considered for selected cases of low libido but is not standard menopausal hormone therapy. Bisphosphonates treat osteoporosis, not vasomotor symptoms. Question 8 A woman who had a total hysterectomy develops severe hot flashes and has no contraindications to hormone therapy. Which regimen is most appropriate? A. Estrogen alone B. Estrogen plus progestogen C. Progestogen alone D. Raloxifene alone Correct Answer: A. Estrogen alone Rationale: After hysterectomy, endometrial protection is no longer needed because the uterus has been removed. Therefore, estrogen alone is usually sufficient for treating menopausal vasomotor symptoms in women without a uterus. Progestogen is added primarily to reduce endometrial risk. Raloxifene may help bone health and reduce breast cancer risk but may worsen hot flashes and is not the best treatment for severe vasomotor symptoms. Question 9 A postmenopausal woman with unexplained vaginal bleeding requests systemic hormone therapy for hot flashes. What is the best initial response? A. Begin estrogen immediately B. Begin estrogen and progestogen immediately C. Evaluate the bleeding before starting systemic hormone therapy D. Treat the bleeding with calcium supplementation Correct Answer: C. Evaluate the bleeding before starting systemic hormone therapy Rationale: Unexplained vaginal bleeding is a contraindication to systemic hormone therapy until it is properly evaluated. The priority is to rule out endometrial hyperplasia, malignancy, or other gynecologic pathology. Starting estrogen, even with progestogen, before evaluation could delay diagnosis. Calcium does not address abnormal bleeding. Safety requires assessment before hormone exposure. Question 10 A breast cancer survivor has troubling hot flashes and wants a non-hormonal option. Which medication is most appropriate based on the provided content? A. Paroxetine B. Systemic estrogen C. Estrogen plus progestogen D. Raloxifene as first-line treatment for hot flashes Correct Answer: A. Paroxetine Rationale: Paroxetine is a non-hormonal option that can reduce menopausal hot flashes and night sweats. It is especially relevant when hormone therapy is inappropriate, such as in many breast cancer survivors. Systemic estrogen is generally avoided in breast cancer survivors unless highly specialized evaluation supports it. Raloxifene may reduce breast cancer risk and improve bone density but can worsen hot flashes. Question 11 A woman with a history of breast cancer needs treatment for hot flashes. Which additional non-hormonal medication may be appropriate? A. Venlafaxine B. Oral estrogen C. High-dose progesterone without evaluation D. Testosterone as first-line therapy Correct Answer: A. Venlafaxine Rationale: Venlafaxine, an SNRI, is used as a non-hormonal treatment for hot flashes and may be appropriate for women with a history of breast cancer. Oral estrogen is usually avoided because of hormone-sensitive cancer concerns. Progesterone without a clear indication is not first-line. Testosterone may help selected cases of decreased libido but is not first-line for vasomotor symptoms in breast cancer survivors. Question 12 A menopausal woman reports hot flashes that disrupt sleep. Which non-hormonal medication may improve both symptoms? A. Gabapentin B. Calcium carbonate C. Vaginal lubricant D. Teriparatide Correct Answer: A. Gabapentin Rationale: Gabapentin can reduce hot flashes and improve sleep disturbances in menopausal women, making it useful when nighttime symptoms are prominent. Calcium carbonate supports bone health but does not treat vasomotor symptoms. Vaginal lubricants relieve dryness during sexual activity. Teriparatide treats osteoporosis by stimulating bone formation but does not address hot flashes or insomnia. A woman with menopausal hot flashes asks about clonidine. Which explanation is most accurate? A. It is an alpha-2 agonist that can reduce hot flash frequency B. It is the most effective therapy for osteoporosis C. It is a vaginal estrogen preparation D. It is contraindicated in all postmenopausal women Correct Answer: A. It is an alpha-2 agonist that can reduce hot flash frequency Rationale: Clonidine is a non-hormonal option that may reduce hot flash frequency. It is not the most effective osteoporosis treatment and does not act as vaginal estrogen. It is not contraindicated in all women, though side effects and comorbidities must be considered. It may be useful when hormone therapy is inappropriate or not preferred.